News Flash
-
Head Offices
Pharmacy and Poisons Board offices along Lenana Road in Nairobi. The building was officially opened in 2005 by the Minister of Health at the time, Hon. Charity Ngilu. -
PV Launch
Pharmacovigilance department came out to the Kenyan public on the 9th of June 2009 when a formal launch of the Pharmacovigilance System in Kenya took place at the Panafric Hotel in Nairobi. -
NQCL
National Quality Control Laboratory. The quality of a drug is one of the criteria for market approval. Quality assurance covers all activities aimed at ensuring that consumers and patients receive a product that meets established specifications and standards of quality, safety an efficacy. -
Ministry of Health HQ
Pharmacy and Poisons Board is under the Ministry of Health whose HQ are at Afya House, Bishop Road, Nairobi -
Guidelines
The Pharmacy and Poisons Board has various guidelines that explain how services are delivered. The guidelines can be downloaded from this site.
E-Shots
DHCP B Immune Recall - Pdf
Suspected Adverse Drug Reaction Reporting Form (Yellow Form) - Pdf
Suspected Lack of Efficacy: Tocinox 5 i.u./mL injections - Pdf
Pharmacy and Poisons Board Supplement in the Newspapers - Pdf
Voluntary Product Recall- certain batches of Typhim Vi (Typhoid vaccine) by Sanofi Pasteur - Pdf
Falsified Nilzan Plus with Cobalt Liquid (Veterinary product) - Pdf
Withdrawal of Xigris (Drotrecogin Alfa) from the market - Pdf
Counterfeit Postinor - Doc
Illegal Distribution of FUZOL - Doc
Complaints Dextrose - Doc
Poor Quality FLAGIMED - Doc
Clinical Guidelines for Management and Referral of Common Conditions at Level 1: Community -Doc
Clinical Guidelines for Management and Referral of Common Conditions at Level 2-3: Primary Care -Doc
Clinical Guidelines for Management and Referral of Common Conditions at Level 4-6: Hospitals - Doc
Poor Quality Paracetamol - Doc
Poor Quality Benzylpenicillin - Doc
National Guidelines for the Diagnosis, Treatment and Prevention of Malaria in Kenya - Doc
Photosensitivity reactions- reminder to all health-care professionals of the risk of photosensitivity reactions with a number of topical and systematic medicines - Doc
Voluntary Recall of Polaramine Expectorant - Doc
Suspension of Market Authorization for Rosiglitazone and Rosiglitazone-containing products - Doc
Suspension of Market Authorization for Sibutramine and Sibutramine-containing products - Doc
Kenya Becomes 98th Full Member of the WHO Programme for International Drug Monitoring - Doc
Updated recommendations concerning the interaction with calcium-containing products Ceftriaxone- Doc